MT-2 (Melanotan-2) Research Overview

MT-2 (Melanotan-2) is a synthetic cyclic analog of alpha-melanocyte-stimulating hormone (α-MSH). It is used as a reference compound in laboratory studies of melanocortin receptor binding, pathway selectivity, and downstream signalling. This overview is limited to compound identity and controlled research observations.

Molecular identity

MT-2 is commonly described as the cyclic heptapeptide cyclo[Nle4, D-Phe7]-α-MSH(4-10), with a molecular mass of approximately 1,024.2 Da. The cyclic lactam structure distinguishes it from the linear parent sequence and is studied for its relationship to receptor affinity and peptide stability.

• Compound: MT-2 (Melanotan-2)
• Parent sequence: α-MSH
• Structure: Synthetic cyclic heptapeptide analog
• Research class: Broad melanocortin receptor agonist
• Principal receptor panel: MC1R, MC3R, MC4R, and MC5R

Melanocortin receptor framework

The melanocortin family contains five G-protein-coupled receptor subtypes. MT-2 is studied as a broad agonist rather than a subtype-selective reference. Binding assays and functional models compare affinity, cyclic-AMP response, and downstream pathway markers across receptor subtypes.

MC1R-focused studies examine signalling in pigment-producing cell systems, including cyclic-AMP response, PKA activation, MITF regulation, and expression of melanogenic-pathway enzymes. MC3R and MC4R models help researchers distinguish central signalling patterns, while MC5R work examines a separate receptor distribution and signalling profile. These receptor-level observations do not make the subtypes interchangeable.

Pigmentation-related cellular endpoints

Pigmentation-related research measures molecular and cellular endpoints rather than consumer outcomes. Common endpoints include MC1R activation, intracellular cyclic-AMP concentration, MITF expression, tyrosinase-pathway activity, and eumelanin-to-pheomelanin ratios in controlled models.

The relevance of MT-2 in this literature comes from its α-MSH-derived sequence and broad receptor activity. Results depend on model design, receptor expression, analytical method, and reference controls, so findings should be interpreted within the conditions of each experiment.

MT-2, MT-1, and afamelanotide are distinct

MT-2 is a cyclic heptapeptide analog with broad melanocortin receptor activity. MT-1/afamelanotide is a distinct, longer linear analog with a different selectivity profile. Their names, structures, catalog records, and analytical documentation should not be combined.

Analytical verification

Researchers should match any analytical report to the batch identifier printed on the vial. Identity and purity methods may include chromatographic and mass-spectrometric analysis, but the available report must be checked for the specific lot rather than inferred from a general standard.

Review the current MT-2 (Melanotan-2) research material page for specifications, the public COA lookup, and verification status.

Research limitations

MT-2 findings are model-dependent, and receptor activity can vary with assay design, expression system, concentration range, and endpoint selection. A broad agonist profile also means that results from one receptor subtype cannot automatically be assigned to another. Reproducible work therefore requires clear controls, documented material identity, and batch-level traceability.

References

1. Hruby VJ, et al. Cyclic lactam analogues of α-MSH and melanocortin receptor research. *Journal of Medicinal Chemistry*.
2. Hadley ME, Dorr RT. Melanocortin peptide research: historical milestones and receptor pharmacology. *Peptides*. 2006;27(4):921–930.
3. Mountjoy KG. Melanocortin receptors and their cellular signalling pathways. *Molecular and Cellular Endocrinology*.

Running the numbers for a protocol? Use the research calculators to convert mg, mL, and syringe units.